Established in May 2016, The AMR Centre is a key part of the UK’s response to the global threat from Antimicrobial Resistance. Based at Alderley Park, The AMR Centre is a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics through a fully integrated development capability, offering translational R&D from pre-clinical hits through to clinical proof of concept.
For over 65 years, INFORS HT has been at the forefront of developing and producing high-tech solutions for the biotechnology sector. Renowned for their Swiss engineering excellence, INFORS HT specializes in bioreactors, shaker incubators, and bioprocess control software. The company's innovative approach is dedicated to optimizing biotechnological workflows through cutting-edge technologies and close customer collaboration. Their comprehensive product range, from benchtop shakers and bioreactors up to large-scale stacked GMP ready incubator shakers and 2000l stainless steel pilot bioreactor systems supporting the full spectrum of bioprocess development needs. Utilized globally in advanced fields such as bioprocess development, industrial biotechnology, synthetic biology, and advanced materials, INFORS HT continues to lead the industry. With headquarters in Bottmingen, Switzerland, and a commitment to unparalleled quality and innovation, INFORS HT empowers scientists and researchers to achieve top-of-class results.
For more information, please visit https://www.infors-ht.com
For more information, please visit https://www.infors-ht.com
Inivata is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment.. . Inivata works with leaders in industry and academic research to develop new clinical applications for ctDNA analysis which will bring real benefits to physicians, patients, pharmaceutical companies and payers. Inivata’s goal is to provide physicians with the information they need, to provide the best outcomes for patients and effective design for clinical trials.. . Inivata is based in Cambridge, UK and its scientific founders are leading figures in the ctDNA field: Nitzan Rosenfeld (Cancer Research UK Cambridge Institute, University of Cambridge), Tim Forshew (UCL Cancer Institute, University College London), James Brenton (Cancer Research UK Cambridge Institute, University of Cambridge) and Davina Gale (Cancer Research UK Cambridge Institute, University of Cambridge).. . The Company has a comprehensive understanding of cancer genomics and circulating DNA. It is applying its enhanced TAm-Seq approach and cutting-edge technologies to address critical clinical decision points in cancer care and cancer drug development, alongside pharmaceutical partners, leading clinicians and academic groups.
GB Innomech excels at developing and producing innovative electro-mechanical prototypes, batch production and flexible automated manufacturing systems.. With over 20 years' experience producing equipment for customers from many industrial sectors, our committed team has skills in production, engineering and design with air-conditioned workshop, machining and fabrication facilities. In addition to our bespoke systems, we provide a repeat build service for small volume, high value products which we can install, train and service throughout the world. Our risk-based approach, where we undertake risk assessments throughout the project, has led to a strong reputation for providing innovative solutions within regulated environments.
No data available
No data available
IONTAS is a privately owned, profitable, biotechnology company, offering services and technologies to the global biotechnology community. Our expertise focuses on phage display and technologies for therapeutic antibody discovery. IONTAS scientific staff have been at the forefront of phage display technology, mammalian display and generating antibodies against ion channels
Stabilitech has developed a proprietary technology for stabilisation of vaccines and biopharmaceuticals, removing the need for refrigeration.. . Stabilitech started research in late 2004, and received its first significant funding in 2007, from business angels. . Stabilitech has developed a novel proprietary technology which stabilizes vaccines (including live viruses, inactivated viruses and subunit vaccines), biopharmaceuticals (including antibodies, enzymes, growth factors etc) and other biological products. . Stabilitech is based in the Imperial College incubator, and currently has 5 employees.
No data available
Isomerase is a synthetic biology and bioprocess innovation partner helping companies develop new products or processes through harnessing bacteria and fungi to discover and produce native or novel molecules sustainably, cost effectively and at scale. We engineer microbial strains, develop then improve production processes using upstream and downstream process development at our bioprocess facility and help partners tech transfer their process to scale. The three main products we work on are:
(1) Natural Products - we help partners to access and work with rare and hard-to-source natural products and producing strains, to produce novel analogues of microbial natural products and to scale-up their production.
(2) Recombinant Peptides – working in E. coli or Pichia we can develop scalable manufacturing processes designed to compete economically with synthetic processes, especially at scale.
(3) Biocatalytic Enzymes - we support the discovery and production of microbial enzymes for manufacture in our proprietary E. coli or Pichia systems and help to produce them at laboratory and pilot scale, to generate robust processes for their production and to tech transfer these processes to CDMOs enabling phase-appropriate larger scale manufacture.
Isomerase operates B2B with companies wanting to benefit from our microbial expertise to generate value in their products and progress their processes toward commercialisation. Isomerase has worked with companies throughout Europe and North America, ranging in size from two-person virtual operations to multinational companies serving a range of industries including pharmaceutical, diagnostic, agritech, consumer goods and functional materials.
(1) Natural Products - we help partners to access and work with rare and hard-to-source natural products and producing strains, to produce novel analogues of microbial natural products and to scale-up their production.
(2) Recombinant Peptides – working in E. coli or Pichia we can develop scalable manufacturing processes designed to compete economically with synthetic processes, especially at scale.
(3) Biocatalytic Enzymes - we support the discovery and production of microbial enzymes for manufacture in our proprietary E. coli or Pichia systems and help to produce them at laboratory and pilot scale, to generate robust processes for their production and to tech transfer these processes to CDMOs enabling phase-appropriate larger scale manufacture.
Isomerase operates B2B with companies wanting to benefit from our microbial expertise to generate value in their products and progress their processes toward commercialisation. Isomerase has worked with companies throughout Europe and North America, ranging in size from two-person virtual operations to multinational companies serving a range of industries including pharmaceutical, diagnostic, agritech, consumer goods and functional materials.